Aurinia Pharmaceuticals (AUPH) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 36.7% versus a loss of 31.3%. Over five years, NAMS leads with a +126.0% price change compared with -22.2% for AUPH. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.49 billion vs $2.16 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | NAMS |
|---|---|---|
| Share price | $16.22 | $21.26 |
| Market cap | $2.16B | $2.49B |
| 1-day change | +1.31% | -3.93% |
| YTD return | +0.38% | -36.92% |
| 1-year return | +36.72% | -31.29% |
| 5-year return | -22.17% | +126.05% |
| P/E ratio (TTM) | 7.11 | — |
| Forward P/E | 15.21 | — |
| EPS (TTM) | $2.28 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | — | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $19.25 | $42.21 |
| 52-week low | $10.90 | $20.94 |
| Distance from 52-week high | -15.74% | -49.63% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +10.11% | +133.54% |
| Average volume | 988.90K | 1.35M |
| Shares outstanding | 133.05M | 116.90M |
| Employees | 128 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed NAMS by 68.0 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
AUPH vs NAMS FAQ
Which is bigger, Aurinia Pharmaceuticals or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.49B compared with $2.16B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or NAMS?
AUPH returned +36.72% over the past 12 months, compared with -31.29% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.